Hi friends, it's #Prostate Cancer Friday! Here are Top Posts of the Week 🧵
1/ @neerajaiims on the FDA approval of capivasertib for mHSPC/APMS prostate cancer:
https://t.co/ko0gAhKiPR
Today I learned about @OpenMedicineHQ and their endeavors in building user friendly algorithms to aid with oncology care and treatment decisions. @allisonoconn@grace_ferri.
Hi friends, it's #LungCancer Wednesday! Here are Top Posts of the Week 🧵
1/ @StephenVLiu on an analysis of patients receiving IO for NSCLC:
https://t.co/t63DsHtZQD
Hi friends, it's #BreastCancer Tuesday! Here are Top Posts of the Week 🧵
1/ @dr_yakupergun with a case on metastatic HR−/HER2+ breast cancer:
https://t.co/nNgkuq3Qpx
Hi friends, it's #AcuteMyeloidLeukemia Thursday! #EHA2026 edition 🎉🎉🎉
Here are Top Posts of the Week 🧵
1/ @Dr_AmerZeidan on a decade of progress in treating AML:
https://t.co/1cSjyVXBz2
Hi friends, it's #LungCancer Wednesday! Here are Top Posts of the Week 🧵
1/ @jennifermarksmd on neoadjuvant lorlatinib in stage 2 ALK+ NSCLC: https://t.co/pEIRWGo5Lm
#ASCO26 through an algorithm lens
@ASCO
LIBRETTO-432 / LBA3
Primary publication in NEJM:
https://t.co/epek0iUjjv
Clinical decision point:
In early-stage NSCLC, should comprehensive molecular testing at diagnosis guide adjuvant targeted therapy after definitive local treatment?
LIBRETTO-432 tested adjuvant selpercatinib vs placebo in early-stage RET fusion–positive NSCLC after definitive therapy.
Key data:
• global phase III randomized trial
• 151 patients with stage IB–IIIA RET fusion–positive NSCLC
• selpercatinib for up to 3 years
• primary efficacy population: stage II–IIIA
• median EFS: not reached vs 31.8 months
• 2-year EFS: 91.5% vs 61.1%
• EFS HR: 0.172
• OS immature
@lungoncdoc@StephenVLiu@GlopesMd@ADesaiMD@M_Torasawa@Tony_Calles
Potential algorithm impact:
LIBRETTO-432 changes the early-stage NSCLC algorithm at the testing node.
The key step is not only:
“Which adjuvant treatment?”
It is:
“Was molecular testing done early enough to identify the adjuvant option?”
A future pathway should include:
Diagnose potentially curable NSCLC
Stage accurately
Preserve tissue for comprehensive molecular testing
Test for actionable drivers, including RET fusions
Complete surgery or definitive radiation ± systemic therapy when indicated
If RET fusion-positive and eligible: consider adjuvant selpercatinib
Monitor liver enzymes, blood pressure, diarrhea, dry mouth, QT/drug interactions and adherence
Continue surveillance and long-term follow-up
Bottom line:
LIBRETTO-432 is not only an adjuvant RET-inhibitor trial.
It is an early-stage molecular-testing trial in practice.